A phase III placebo-controlled trial of tasimelteon in patients with Smith-Magenis Syndrome
Phase of Trial: Phase III
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Tasimelteon (Primary)
- Indications Developmental disabilities
- Focus Therapeutic Use
- 02 Nov 2016 According to a Vanda Pharmaceuticals media release, enrollment in this trial began in the fourth quarter of 2016.
- 02 Nov 2016 According to a Vanda Pharmaceuticals media release, status changed from planning to recruiting.
- 13 Feb 2016 New trial record